Caldwell Sutter Capital, Inc. Autolus Therapeutics PLC Transaction History
Caldwell Sutter Capital, Inc.
- $215 Billion
- Q4 2024
A detailed history of Caldwell Sutter Capital, Inc. transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Caldwell Sutter Capital, Inc. holds 500 shares of AUTL stock, worth $960. This represents 0.0% of its overall portfolio holdings.
Number of Shares
500Holding current value
$960% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding AUTL
# of Institutions
112Shares Held
166MCall Options Held
2.8KPut Options Held
13.4K-
Wellington Management Group LLP Boston, MA25.3MShares$48.7 Million0.01% of portfolio
-
Blackstone Inc New York, NY20.5MShares$39.3 Million0.35% of portfolio
-
Syncona Portfolio LTD Guernsey, Channel Islands, X016.6MShares$32 Million73.83% of portfolio
-
Deep Track Capital, LP Greenwich, CT15.3MShares$29.3 Million2.04% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.3MShares$23.7 Million0.67% of portfolio
About Autolus Therapeutics plc
- Ticker AUTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 90,909,800
- Market Cap $175M
- Description
- Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...